These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15617300)

  • 1. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 2. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous administration rather than swallowing].
    Schubert-Zsilavecz M
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515258
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 5. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.
    Arikian SR; Casciano J; Doyle JJ; Tarride JE; Casciano RN
    Manag Care Interface; 2000 Feb; 13(2):88-94. PubMed ID: 11067391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin transdermal (Oxytrol) for overactive bladder.
    Med Lett Drugs Ther; 2003 May; 45(1156):38-9. PubMed ID: 12736598
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
    Versi E; Appell R; Mobley D; Patton W; Saltzstein D
    Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
    Arango Toro O; Nohales Taurines G; Cortadellas Angel R; Castro Santamaría R; Gelabert Mas A
    Actas Urol Esp; 1998 Feb; 22(2):124-30. PubMed ID: 9586268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transdermal system].
    Krankenpfl J; 2005; 43(4-6):94. PubMed ID: 16171045
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe Xerostomia Secondary to Anticholinergic Drug Therapy: Case Report.
    Brown RS; Rhodes BH; Siewe MS; Matthews TJ
    Dent Today; 2017 Feb; 36(2):136-8. PubMed ID: 29235767
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].
    Johansen JK; Lose G
    Ugeskr Laeger; 1999 Nov; 161(44):6052-5. PubMed ID: 10778341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 20. Transdermal oxybutynin. A viewpoint by Michael Chancellor.
    Chancellor M
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.